A Phase II Study of Combined Chemotherapy with 5-Week Cycles of S-1 and CPT-11 plus Bevacizumab in Patients with Metastatic Colon Cancer-Reference-Cited by-同舟云学术

A Phase II Study of Combined Chemotherapy with 5-Week Cycles of S-1 and CPT-11 plus Bevacizumab in Patients with Metastatic Colon Cancer

Published:2013 Issue:6 Volume:85 Page:317-322
ISSN:0030-2414
Container-title:Oncology
language:en
Short-container-title:Oncology

Author:

Mizushima Tsunekazu,Ide Yoshito,Murata Kohei,Ohashi Ichiro,Yasumasa Keigo,Fukunaga Mutsumi,Takemoto Hiroyoshi,Tamagawa Hiroshi,Hasegawa Junichi,Hata Taishi,Takemasa Ichiro,Ikeda Masataka,Yamamoto Hirofumi,Sekimoto Mitsugu,Nezu Riichiro,Doki Yuichiro,Mori Masaki,

Publisher

S. Karger AG

Subject

Cancer Research,Oncology,General Medicine

Reference17 articles.

1. Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer

2. A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer

3. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

4. Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Leucovorin Plus Oxaliplatin in Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group

5. Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral S-1 with 24-h Infusion of Irinotecan plus Bevacizumab versus FOLFIRI plus Bevacizumab as First-Line Chemotherapy for Metastatic Colorectal Cancer: An Open-Label Randomized Phase II Trial;Oncology;2020

2. Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy;Cancer Chemotherapy and Pharmacology;2017-05-16

3. A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer;Oncology;2015-01-09

4. S-1-associated hand-foot syndrome as a prognostic factor in patients with metastatic breast cancer;Annals of Cancer Research and Therapy;2015

5. Genomic Applications in Colorectal and Pancreatic Tumors;Genomic Applications in Pathology;2014-09-05